Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SX3P
Consumer Staples
SX3P
Consumer Staples
SX3P
+0.58%
619.21
+3.56
+0.58%
—615.65615.07619.70614.21——
SX6P
Utilities
SX6P
Utilities
SX6P
-3.70%
530.86
-20.38
-3.70%
—551.24548.70548.70530.09——
SX8P
Technology
SX8P
Technology
SX8P
-1.74%
930.62
-16.46
-1.74%
—947.08946.19946.19917.62——
SXAP
Consumer Discretionary
SXAP
Consumer Discretionary
SXAP
-1.87%
456.05
-8.70
-1.87%
—464.75463.99464.64453.17——
SXDP
Health Care
SXDP
Health Care
SXDP
-0.35%
1,090.63
-3.82
-0.35%
—1,094.451,093.531,102.341,089.23——
SXEP
Energy
SXEP
Energy
SXEP
-0.14%
535.34
-0.73
-0.14%
—536.07535.49537.10532.16——
SXFP
Financials
SXFP
Financials
SXFP
-0.53%
890.23
-4.73
-0.53%
—894.96895.33896.45886.07——
SXKP
Communications
SXKP
Communications
SXKP
-1.11%
312.78
-3.52
-1.11%
—316.30317.30317.88312.06——
SXNP
Industrials
SXNP
Industrials
SXNP
-2.47%
1,095.60
-27.75
-2.47%
—1,123.351,118.991,118.991,092.58——
SXPP
Materials
SXPP
Materials
SXPP
-5.11%
818.07
-44.02
-5.11%
—862.09841.63841.63810.46——
Q4 2026 earnings • released • Revenue miss -2.06%
See results
4502:TYO
Takeda Pharmaceutical Co Ltd
¥5,259.00
-0.34%
(-18.00) 1D
May 18, 9:40:45 AM GMT+9  ·   JPY
All symbols
SymbolPriceChange% Change
Generating top insights for 4502...
Open
¥5,291
High
¥5,309
Low
¥5,244
Mkt. cap
8.39T
Avg. vol.
4.24M
Volume
697.80K
Dividend
3.80%
Quarterly dividend
¥50
Ex dividend date
Sep 29, 2025
P/E ratio
43.20
52-wk high
¥6,033
52-wk low
¥4,086
EPS
¥122
Shares outstanding
784.48M
No. of employees
47K
News stories
From sources across the web
Profile
The Takeda Pharmaceutical Company Limited is a Japanese multinational pharmaceutical company. It is the third largest pharmaceutical company in Asia, behind Sinopharm and Shanghai Pharmaceuticals, and one of the top 20 largest pharmaceutical companies in the world by revenue. The company has over 49,578 employees worldwide and achieved US$19.299 billion in revenue during the 2018 fiscal year. The company is focused on oncology, rare diseases, neuroscience, gastroenterology, plasma-derived therapies and vaccines. Its headquarters is located in Chuo-ku, Osaka, and it has an office in Nihonbashi, Chuo, Tokyo. In January 2012, Fortune Magazine ranked the Takeda Oncology Company as one of the 100 best companies to work for in the United States. As of 2015, Christophe Weber was appointed as the CEO and president of Takeda. Wikipedia
About Takeda Pharmaceutical Co Ltd
CEOChristophe Weber | Christophe Weber
Employees47.5K
FoundedJun 12, 1781
Headquarters-
SectorPharmaceutical industry
Websitetakeda.com
Last report
May 13, 2026
Fiscal Period
Q4 2026
EPS / Est. (JPY)
- / -
Revenue / Est. (JPY)
1.09T / 1.12T
Fiscal Q4 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in JPY
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in JPY
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
1.11T
1.11T
1.19T
1.09T
Cost of goods sold
384.68B
380.06B
401.15B
405.70B
Cost of revenue
384.68B
380.06B
401.15B
405.70B
Research and development expenses
143.89B
161.48B
175.23B
195.30B
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
255.88B
253.55B
282.78B
292.00B
Operating expense
535.14B
562.57B
661.30B
655.00B
Total operating expenses
919.82B
942.63B
1.06T
1.06T
Operating income
186.86B
170.17B
129.25B
33.80B
Other non operating income
-77.96B
77.96B
8.80B
100.00M
EBT including unusual items
150.63B
28.17B
133.86B
-52.50B
EBT excluding unusual items
152.93B
128.86B
114.17B
-5.00B
Income tax expense
26.35B
39.90B
30.13B
-28.20B
Effective tax rate
17.49%
141.64%
22.51%
53.71%
Other operating expenses
6.03B
16.12B
67.13B
60.30B
Net income
124.24B
-11.80B
103.64B
-24.40B
Net profit margin
11.23%
-1.06%
8.70%
-2.23%
Earnings per share
-
-
-
-
Interest and investment income
73.76B
43.92B
93.00B
15.80B
Interest expense
-29.20B
-161.10B
-117.68B
-54.30B
Net interest expenses
44.56B
-117.18B
-24.68B
-38.50B
Depreciation and amortization charges
-
-
-
-
EBITDA
368.50B
355.15B
182.70B
594.57B
Gain or loss from assets sale
-17.32B
303.00M
358.00M
1.46B
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer